Have a Claim?

Click here for a confidential contact or call:

1-212-350-2764

July 1, 2020

Posted  July 1, 2020

Novartis Pharmaceuticals Corporation will pay $51.25 million to resolve claims that it unlawfully funneled money to three different foundations – The Assistance Fund, the National Organization for Rare Disorders, and the Chronic Disease Fund – so that those organizations could fund co-payments owed by Medicare beneficiary patients prescribed the Novartis drugs Gilenya (for multiple sclerosis) and Afinitor (for renal cell carcinoma and certain pancreatic cancers).  The payments were alleged to be in violation of the Anti-Kickback Statute and False Claims Act.  USAO Mass; DOJ

Tagged in: Anti-Kickback and Stark, Drug and DME Pricing, FCA Federal, Healthcare Fraud, Pharma Fraud,

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: